Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
10.1016/S1473-3099(21)00125-0
Saved in:
Similar Items
-
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
by: Natasha Howard, et al.
Published: (2023) -
A social scientist's take on vaccine efficacy
by: Contreras, Antonio P.
Published: (2021) -
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries
by: Badio, Moses, et al.
Published: (2021) -
DIFFERENT MECHANISMS DETERMINE PLAQUE SIZE IN ATTENUATED AND UNDERATTENUATED VACCINE STRAINS
by: GOH CHOON MENG KENNETH
Published: (2016) -
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children
by: Lum, L.C.S., et al.
Published: (2011)